Synairgen and Pharmaxis are preparing a Phase 1 clinical trial of PXS-5382A for pulmonary fibrosis and other tissue-scarring disorders. Positive results of preclinical-trial studies on the therapy’s pharmacology — the way it works — and toxicology paved the way for the trial, the company said. PXS-5382A blocks an enzyme known…
Synairgen and Pharmaxis Preparing Phase 1 Trial of Potential Fibrosis Therapy
Pulmonary fibrosis (PF) is a chronic lung disease where the tissue in the lungs becomes scarred and stiffens over time. Like all diseases, PF does not discriminate and there have been many celebrities who have suffered from the condition. Sadly, some have lost their lives to the disease. According to …
A combination of Ofev (nintedanib) and Esbriet (pirfenidone) is as safe a therapy for idiopathic pulmonary fibrosis as the individual components alone, a Phase 4 clinical trial indicates. Preliminary trial findings also suggested that the combination might be more effective than either therapy alone, although researchers said this needs to…
I have experienced a whirlwind of emotions, good and bad, since being diagnosed with IPF. Sometimes I feel these emotions randomly, and other times they are attributed to how my day has gone overall. For example, if I have had a good day physically when my breathing…
Boehringer Ingelheim has extended its collaboration with Inventiva on developing treatments for tissue-scarring conditions such as idiopathic pulmonary fibrosis, or IPF. The company exercised an option to continue the partnership, which began in 2016. A joint research team has identified a target for a fibrosis therapy, and preliminary results indicate…
When Susan Arick Spears learned of her father’s illness, she felt blindsided. “I hung up the phone and just stared out the window. For hours.” The call came in October 2016, she said in a recent interview with Pulmonary Fibrosis News, while she was traveling with her work. First, the doctor talked with her…
miRagen Therapeutics will release preclinical data supporting an inhaled version of its investigational treatment MRG-201 for idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society (ERS) International Congress that opens Saturday. At the meeting, which runs Sept. 9–13 in Milan, Italy, miRagen will present the poster, “Feasibility, distribution, and efficacy of…
Since I received my IPF diagnosis about 16 months ago, there have been many times when things in my life have felt out of my control. For example, I neither can control how rapidly my disease is progressing, nor the physical limitations that I have due to…
Did you know that pulmonary fibrosis takes as many lives as breast cancer or prostate cancer? However, unlike breast and prostate cancer, there is no remission and treatment can only ease the symptoms. Elicia Shepard is one person trying to raise the profile of the disease and in this…
The Pulmonary Fibrosis Foundation is marking Pulmonary Fibrosis Awareness Month in September with a range of festivities across the United States. Some of the activities will allow patients, caregivers, and healthcare professionals to share their stories and knowledge with each other. The first event will be the inaugural walk…
